Which has stronger valuation and earnings, CLYM or PEPG?

Climb Bio is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.83 N/A PepGen N/A N/A -$89.65M -$1.31 N/A

Is CLYM or PEPG more profitable?

Climb Bio's return on equity of -31.79% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.79% -30.79% PepGen N/A -51.01% -43.49%

Does the media prefer CLYM or PEPG?

In the previous week, Climb Bio had 5 more articles in the media than PepGen. MarketBeat recorded 10 mentions for Climb Bio and 5 mentions for PepGen. PepGen's average media sentiment score of 0.94 beat Climb Bio's score of 0.90 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, CADL or PEPG?

Candel Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$1.41 N/A PepGen N/A N/A -$89.65M -$1.31 N/A

Is CADL or PEPG more profitable?

PepGen's return on equity of -51.01% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -76.98% -48.50% PepGen N/A -51.01% -43.49%

Does the media prefer CADL or PEPG?

In the previous week, Candel Therapeutics had 2 more articles in the media than PepGen. MarketBeat recorded 7 mentions for Candel Therapeutics and 5 mentions for PepGen. PepGen's average media sentiment score of 0.94 beat Candel Therapeutics' score of 0.92 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PEPG or PHAR more profitable?

Pharming Group has a net margin of 2.51% compared to PepGen's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -51.01% -43.49% Pharming Group 2.51% 3.40% 1.90%

Does the media prefer PEPG or PHAR?

In the previous week, Pharming Group had 6 more articles in the media than PepGen. MarketBeat recorded 11 mentions for Pharming Group and 5 mentions for PepGen. Pharming Group's average media sentiment score of 1.09 beat PepGen's score of 0.94 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DBVT or PEPG more profitable?

PepGen has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. PepGen's return on equity of -51.01% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -3,506.53% -119.33% -84.43% PepGen N/A -51.01% -43.49%

Does the media prefer DBVT or PEPG?

In the previous week, PepGen had 2 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for PepGen and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.07 beat PepGen's score of 0.94 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PepGen (PEPG) Competitors

$2.98 -0.04 (-1.32%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.06 +0.08 (+2.68%)

As of 09/11/2026 07:30 PM Eastern

Compare

PEPG vs. CLYM, CADL, SLN, PHAR, and DBVT

Should you buy PepGen stock or one of its competitors? PepGen's main competitors and comparable companies include Climb Bio (CLYM), Candel Therapeutics (CADL), Silence Therapeutics (SLN), Pharming Group (PHAR), and DBV Technologies (DBVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does PepGen compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Climb Bio's return on equity of -31.79% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
PepGen	N/A	-51.01%	-43.49%

Climb Bio is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

Climb Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, PepGen has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market.

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Climb Bio presently has a consensus target price of $26.92, suggesting a potential upside of 88.93%. PepGen has a consensus target price of $11.50, suggesting a potential upside of 285.91%. Given PepGen's higher possible upside, analysts plainly believe PepGen is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Climb Bio had 5 more articles in the media than PepGen. MarketBeat recorded 10 mentions for Climb Bio and 5 mentions for PepGen. PepGen's average media sentiment score of 0.94 beat Climb Bio's score of 0.90 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Climb Bio beats PepGen on 10 of the 14 factors compared between the two stocks.

How does PepGen compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

PepGen's return on equity of -51.01% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
PepGen	N/A	-51.01%	-43.49%

Candel Therapeutics has a beta of -0.48, meaning that its share price is 148% less volatile than the broader market. Comparatively, PepGen has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Comparatively, 1.3% of PepGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Candel Therapeutics currently has a consensus target price of $19.29, indicating a potential upside of 82.80%. PepGen has a consensus target price of $11.50, indicating a potential upside of 285.91%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Candel Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

In the previous week, Candel Therapeutics had 2 more articles in the media than PepGen. MarketBeat recorded 7 mentions for Candel Therapeutics and 5 mentions for PepGen. PepGen's average media sentiment score of 0.94 beat Candel Therapeutics' score of 0.92 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PepGen beats Candel Therapeutics on 9 of the 13 factors compared between the two stocks.

How does PepGen compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, PepGen had 4 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for PepGen and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.18 beat PepGen's score of 0.94 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silence Therapeutics	Positive
PepGen	Positive

Silence Therapeutics has higher revenue and earnings than PepGen. Silence Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,399.88	-$88.61M	-$1.28	N/A
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

PepGen has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. PepGen's return on equity of -51.01% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
PepGen	N/A	-51.01%	-43.49%

Silence Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, PepGen has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market.

Silence Therapeutics currently has a consensus price target of $53.50, indicating a potential upside of 310.91%. PepGen has a consensus price target of $11.50, indicating a potential upside of 285.91%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Silence Therapeutics is more favorable than PepGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 1.3% of PepGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Silence Therapeutics beats PepGen on 9 of the 16 factors compared between the two stocks.

How does PepGen compare to Pharming Group?

PepGen (NASDAQ:PEPG) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

58.0% of PepGen shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 1.3% of PepGen shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

PepGen has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

PepGen currently has a consensus target price of $11.50, indicating a potential upside of 285.91%. Pharming Group has a consensus target price of $38.67, indicating a potential upside of 244.93%. Given PepGen's stronger consensus rating and higher possible upside, equities analysts plainly believe PepGen is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Pharming Group had 6 more articles in the media than PepGen. MarketBeat recorded 11 mentions for Pharming Group and 5 mentions for PepGen. Pharming Group's average media sentiment score of 1.09 beat PepGen's score of 0.94 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group has a net margin of 2.51% compared to PepGen's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-51.01%	-43.49%
Pharming Group	2.51%	3.40%	1.90%

Pharming Group has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A
Pharming Group	$376.13M	2.11	$2.85M	$0.12	93.42

Summary

Pharming Group beats PepGen on 10 of the 15 factors compared between the two stocks.

How does PepGen compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, PepGen had 2 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for PepGen and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.07 beat PepGen's score of 0.94 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by company insiders. Comparatively, 1.3% of PepGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PepGen has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. PepGen's return on equity of -51.01% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
PepGen	N/A	-51.01%	-43.49%

DBV Technologies currently has a consensus target price of $48.50, indicating a potential upside of 309.28%. PepGen has a consensus target price of $11.50, indicating a potential upside of 285.91%. Given DBV Technologies' higher probable upside, research analysts plainly believe DBV Technologies is more favorable than PepGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

DBV Technologies has a beta of -0.95, suggesting that its stock price is 195% less volatile than the broader market. Comparatively, PepGen has a beta of 1.97, suggesting that its stock price is 97% more volatile than the broader market.

PepGen has lower revenue, but higher earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	132.11	-$146.95M	-$3.51	N/A
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

Summary

PepGen beats DBV Technologies on 11 of the 15 factors compared between the two stocks.

Get PepGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PEPG vs. The Competition

Export

Metric	PepGen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$206.39M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-2.27	14.18	274.94	25.36
Price / Sales	N/A	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	1.39	15.12	10.33	6.20
Net Income	-$89.65M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-4.18%	-4.34%	-3.32%	-2.35%
1 Month Performance	N/A	0.54%	-0.53%	-3.23%
1 Year Performance	101.35%	40.74%	23.51%	8.79%

PepGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PEPG PepGen	2.7143 of 5 stars	$2.98 -1.3%	$11.50 +285.9%	+101.4%	$206.39M	N/A	N/A	30	News Coverage Analyst Forecast
CLYM Climb Bio	3.1321 of 5 stars	$14.34 -4.1%	$26.92 +87.8%	+533.3%	$823.46M	N/A	N/A	9	Analyst Forecast
CADL Candel Therapeutics	3.3316 of 5 stars	$10.36 -8.6%	$19.29 +86.2%	+120.3%	$792.44M	N/A	N/A	60	News Coverage
SLN Silence Therapeutics	3.0363 of 5 stars	$13.12 -1.4%	$53.50 +307.8%	+188.7%	$790.02M	$560K	N/A	100	Positive News
PHAR Pharming Group	4.3956 of 5 stars	$11.13 +3.0%	$38.67 +247.4%	-23.6%	$787.78M	$376.13M	92.75	280	News Coverage Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PEPG) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PepGen (PEPG) Competitors

PEPG vs. CLYM, CADL, SLN, PHAR, and DBVT

How does PepGen compare to Climb Bio?

Summary

How does PepGen compare to Candel Therapeutics?

Summary

How does PepGen compare to Silence Therapeutics?

Summary

How does PepGen compare to Pharming Group?

Summary

How does PepGen compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PepGen (PEPG) Competitors

PEPG vs. CLYM, CADL, SLN, PHAR, and DBVT

How does PepGen compare to Climb Bio?

Is CLYM or PEPG more profitable?

Which has stronger valuation and earnings, CLYM or PEPG?

Which has more volatility & risk, CLYM or PEPG?

Do insiders & institutionals hold more shares of CLYM or PEPG?

Do analysts recommend CLYM or PEPG?

Does the media prefer CLYM or PEPG?

Summary

How does PepGen compare to Candel Therapeutics?

Is CADL or PEPG more profitable?

Which has more risk and volatility, CADL or PEPG?

Do institutionals and insiders believe in CADL or PEPG?

Do analysts prefer CADL or PEPG?

Which has preferable earnings & valuation, CADL or PEPG?

Does the media prefer CADL or PEPG?

Summary

How does PepGen compare to Silence Therapeutics?

Does the media favor SLN or PEPG?

Which has better valuation and earnings, SLN or PEPG?

Is SLN or PEPG more profitable?

Which has more volatility & risk, SLN or PEPG?

Do analysts rate SLN or PEPG?

Do institutionals & insiders have more ownership in SLN or PEPG?

Summary

How does PepGen compare to Pharming Group?

Do institutionals and insiders believe in PEPG or PHAR?

Which has more volatility and risk, PEPG or PHAR?

Do analysts recommend PEPG or PHAR?

Does the media prefer PEPG or PHAR?

Is PEPG or PHAR more profitable?

Which has stronger earnings & valuation, PEPG or PHAR?

Summary

How does PepGen compare to DBV Technologies?

Does the media prefer DBVT or PEPG?

Do insiders & institutionals believe in DBVT or PEPG?

Is DBVT or PEPG more profitable?

Do analysts recommend DBVT or PEPG?

Which has more risk and volatility, DBVT or PEPG?

Which has higher earnings and valuation, DBVT or PEPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG vs. The Competition

PepGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools